<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00273910</url>
  </required_header>
  <id_info>
    <org_study_id>060069</org_study_id>
    <secondary_id>06-C-0069</secondary_id>
    <nct_id>NCT00273910</nct_id>
    <nct_alias>NCT00304057</nct_alias>
  </id_info>
  <brief_title>Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma</brief_title>
  <official_title>Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High Risk Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the immunization effects of a vaccine for patients who are at risk
      for recurrence of their skin cancer. That is, the risk of cancer is higher if melanoma has
      invaded deep into the skin or lymph nodes. Currently, the only therapy that the U.S. Food and
      Drug Administration (FDA) has approved for preventing recurrence of melanoma is
      alpha-interferon. But the research data are controversial. In this study, the vaccine to be
      used, called gp100, contains a piece of a protein called a peptide, which melanoma cancer
      cells produce.

      Patients 16 and older who have had confirmed melanoma surgically removed and whose tissue
      type is tested as being human leukocyte antigen serotype within HLA-A serotype group
      (HLA-A2), through a specific blood test, may be eligible for this study.

      Up to 132 participants will be enrolled. There will be a physical examination and collection
      of blood samples for tests, and making sure that x-rays and scans are current. Patients will
      be randomly assigned to four groups. Group 1 will receive the peptide with an adjuvant
      (assistant) oil-based liquid called Montanide ISA-51, as an injection in the thigh. Group 2
      will receive gp100, Montanide, and a cream called imiquimod, which the FDA has approved for
      treating genital warts and herpes but that may help immune cells in the skin to recognize the
      vaccine. Imiquimod will be applied to the skin for 5 days. Group 3 will receive gp100 mixed
      in salt water given as several mini-doses under the skin of the thigh. Group 4 will also
      receive several mini-doses of gp100 mixed in saline, as well as imiquimod cream applied to
      the skin for 5 days. All patients will receive the gp100 every 3 weeks for 12 weeks. Every
      dose is a cycle, with four cycles considered a course of therapy. If the melanoma does not
      return or patients do not experience side effects from this therapy, then the courses of
      vaccine will repeated for up to 12 cycles of therapy (3 courses over 33 weeks). Side effects
      of the peptide vaccination include local swelling, swelling of local lymph nodes, bruising,
      and pain and redness at the injection sites. There may be chills or fever. Patients will be
      watched closely for such side effects.

      To study how the vaccine changes the action of cells in the immune system, patients' white
      blood cells (lymphocytes) will be obtained, involving a separate informed consent. The
      procedure, called leukaphersis, requires inserting a needle into the arm, to obtain blood
      going into a machine, which divides the blood into red cells, plasma (or the serum part), and
      lymphocytes. The lymphocytes are removed, and the plasma and red cells returned to the
      patient through a second needle in the other arm. Risks associated with the procedure include
      fainting, which can be prevented by patients' eating before coming to the lab, and bleeding
      and infection at the needle site. Patients will undergo leukapheresis will be done about four
      times: before receiving the vaccine, 3 weeks after the first four doses, and then after 8
      cycles and 12 cycles. Patients assigned to the groups receiving imiquimod will be asked to
      record every time they apply that cream and describe any symptoms developed during the study.
      All patients will be watched closely for any sign that their melanoma has returned. Before
      and throughout the study, multiple blood tests will be conducted.

      The vaccine, Montanide, and imiquimod may increase patients' immune system in fighting off
      new tumors, but that is not known now. However, the study may provide information that will
      be useful in treating melanoma patients in the future.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      A previous clinical trial has been conducted in the Surgery Branch National Cancer Institute
      (NCI) in which gp100 immunizations have been administered to patients with melanoma in the
      adjuvant setting. In this prior protocol, the peptide emulsified in Incomplete Freund's
      Adjuvant was administered subcutaneously using several different schedules and was well
      tolerated except for mild and transient erythema at the site of injection. Each of the
      schedules provided successful immunization although the q3w schedule was the best tolerated
      locally and three courses of immunization appeared to be sufficient using this regimen. An
      important finding from the adjuvant protocol however was the significant increase in immune
      precursors specifically reactive against peptide and tumor that occurred with increasing
      courses of immunization. These findings have encouraged us to now further explore the optimal
      methods for generating immune precursors using the gp100:209-217(210M) peptide by testing the
      impact of an additional immune adjuvant, imiquimod, reported to increase the immunizing
      potential of antigens as well as evaluate an alternate route of injection, intradermal
      administration.

      Objectives:

      The primary objective of this trial is to evaluate the immunologic activity of immunization
      with four different preparations of the gp100:209-217(210M) melanoma antigen peptide and
      potentially select one for further study.

      Eligibility:

      HLA-A 0201 patients, age greater than or equal 16 years, with primary melanomas with lesions
      that are ulcerated and greater than or equal 2mm, or any lesions that are greater than or
      equal 4.0 mm in thickness, or greater than or equal 1 positive lymph node, or local
      recurrence, or resected metastatic disease, within 6 months of surgical resection will be
      considered. Patients who have ocular or mucosal melanoma or who require systemic steroid
      therapy will be excluded. The following patients will also be excluded: have previously been
      immunized with gp100; have known hypersensitivity to any of the agents used in this study;
      have previously received chemotherapy for treatment of melanoma; or who are undergoing or
      have undergone in the past 3 weeks any systemic therapy except surgery for their cancer.

      Design:

      Patients will be randomized into one of the following four arms:

        1. gp100:209-217(210M) peptide emulsified in MONTANIDE ISA-51 or Montanide ISA 51 VG
           injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve
           cycles (33 weeks).

        2. gp100:209-217(210M) peptide emulsified in MONTANIDE ISA-51 or Montanide ISA 51 VG
           injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve
           cycles (33 weeks); following the injection patients will apply imiquimod to the skin at
           the site of injection daily for 5 days.

        3. gp100:209-217(210M) in 0.9% Sodium Chloride Injection injected intradermally on day one
           every three weeks (1 cycle) for a total of twelve cycles (33 weeks).

        4. gp100:209-217(210M) peptide in 0.9% Sodium Chloride Injection injected intradermally on
           day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following
           the injection patients will apply imiquimod to the skin at the site of the injection
           daily for 5 days.

      Immunizations will be administered on an outpatient basis unless side effects or the
      patient's clinical condition warrants hospitalization. Patients will receive full clinical
      evaluation three weeks after 8 cycles and 12 cycles.

      Each of the arms will be conducted using a two-stage optimal design Since the primary
      objective is to select one regimen from among the four on the basis of the immune response,
      this design allows there to be greater than 80% probability of correctly selecting the
      superior arm if there is either a tie in the number of immune responses, or if there is at
      least one more immune response on one arm than the other three arms, and if the true response
      rates are 15%, 15%, 15% and 35%. Initially, 19 patients will be enrolled in each arm and
      evaluated; if 0 to 3 of 19 in an arm have an immune response to T2 cells pulsed with 0.01 M
      peptide after the 4th, 8th, and 12th cycles, no further patients would be randomized to
      receive the peptide on that arm. If at least four immunologic responses are noted after the
      8th cycle, then accrual to 33 patients would take place. If all four arms need to be
      completed and 33 patients need to be completed in each arm, a total of 132 patients are
      required.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunologic Response Rate</measure>
    <time_frame>48 months</time_frame>
    <description>Comparison of six different preparations of the gp100:209-217 (210M) melanoma antigen peptide. The arm with the greater number of immunologic responses will be the one most likely to be selected for future study on the basis of immunization alone. Evidence of immunization consist of at least 10 Elispots/100,000 cells above background. An injection site reaction is not an immune response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>48 months</time_frame>
    <description>Here are the number of participants with adverse events. For a detailed list of adverse events see the adverse event module.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>High-Risk Melanoma</condition>
  <arm_group>
    <arm_group_label>Adj-3 A2 gp209(2M) in IFA SQ (vortex)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gp100:209-217(210M) peptide emulsified in MONTANIDE ISA-51 or Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (vortex)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gp100:209-217(210M) peptide emulsified in MONTANIDE ISA-51 or Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of injection daily for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adj-3 A2 gp209(2M) in saline ID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gp100:209-217(210M) in 0.9% Sodium Chloride Injection injected intradermally on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adj-3 A2 gp209(2M) in saline ID + Imiquimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gp100:209-217(210M) peptide in 0.9% Sodium Chloride Injection injected intradermally on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of the injection daily for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adj-3 A2 gp209(2M) in IFA SQ (2 Syringe)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gp100:209-217(210M) peptide emulsified in Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (2 Syringe)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gp100:209-217(210M) peptide emulsified in Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of injection daily for 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gp100:209-217 (210M)</intervention_name>
    <arm_group_label>Adj-3 A2 gp209(2M) in IFA SQ (vortex)</arm_group_label>
    <arm_group_label>Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (vortex)</arm_group_label>
    <arm_group_label>Adj-3 A2 gp209(2M) in saline ID</arm_group_label>
    <arm_group_label>Adj-3 A2 gp209(2M) in saline ID + Imiquimod</arm_group_label>
    <arm_group_label>Adj-3 A2 gp209(2M) in IFA SQ (2 Syringe)</arm_group_label>
    <arm_group_label>Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (2 Syringe)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montanide ISA-51</intervention_name>
    <arm_group_label>Adj-3 A2 gp209(2M) in IFA SQ (vortex)</arm_group_label>
    <arm_group_label>Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (vortex)</arm_group_label>
    <arm_group_label>Adj-3 A2 gp209(2M) in IFA SQ (2 Syringe)</arm_group_label>
    <arm_group_label>Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (2 Syringe)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod</intervention_name>
    <description>Apply imiquimod 5% cream to the skin at the site of injection daily for 5 days</description>
    <arm_group_label>Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (vortex)</arm_group_label>
    <arm_group_label>Adj-3 A2 gp209(2M) in saline ID + Imiquimod</arm_group_label>
    <arm_group_label>Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (2 Syringe)</arm_group_label>
    <other_name>Aldara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        HLA-A 0201 patients, age greater than or equal to 16 years, primary melanomas with lesions
        that are ulcerated and greater than or equal to 2mm, or any lesions that are greater than
        or equal to 4.0 mm in thickness, or greater than or equal to1 positive lymph node, or local
        recurrence, or resected metastatic disease, within 6 months of surgical resection will be
        considered. Patients must be clinically disease free at the time of protocol entry as
        documented by radiologic studies within 6 weeks of patient entry.

        Serum creatinine of 2.0 mg/dl or less

        Total bilirubin 1.6 mg/dl or less, except for patients with Gilbert's Syndrome who must
        have a total bilirubin less than 3.0 mg/dl.

        WBC 3000/mm^3 or greater,

        Platelet count 90,000 mm^3 or greater,

        Serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) less than three times
        normal,

        Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

        Patients of both genders must be willing to practice effective birth control during this
        trial because the potential for teratogenic effects are unknown.

        Patients may have had prior adjuvant treatment with immunotherapy, including interferon, as
        long as 3 weeks have elapsed since prior systemic therapy.

        EXCLUSION CRITERIA:

        Patients will be excluded:

        Who have ocular or mucosal melanoma.

        Who are undergoing or have undergone in the past 3 weeks any systemic therapy except
        surgery for their cancer, and must have recovered to a grade I from any adverse effects of
        treatment prior to entry, other than those that do not have clinical implications, e.g.
        vitiligo, alopecia.

        Have active systemic infections, autoimmune disease or any known immunodeficiency disease.

        Who require systemic steroid therapy.

        Who are pregnant (because of possible side effects on the fetus) or breastfeeding because
        of unknown effects on the developing child).

        Who are known to be positive for hepatitis BsAG or human immunodeficiency virus (HIV)
        antibody (because of possible immune effects of these conditions).

        Who have any form of autoimmune disease (such as autoimmune colitis or Crohn's Disease) or
        immunodeficiency as evidenced by abnormal white blood count (WBC) count 8 and/or presence
        of opportunistic infections. Must have recovered immune competence after radiation therapy.
        (The experimental treatment being evaluated in this protocol depends on an intact immune
        system. Patients who have decreased immune competence may be less responsive to the
        experimental treatment and more susceptible to its toxicities.)

        Who have previously been immunized with gp100.

        Who have known hypersensitivity to any of the agents used in this study.

        Who have previously received chemotherapy for treatment of melanoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A Rosenberg, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, National Institutes of Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Institute (NCI)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/detail/A_2006-C-0069.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3515-9.</citation>
    <PMID>8170938</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2006</study_first_submitted>
  <study_first_submitted_qc>January 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2006</study_first_posted>
  <results_first_submitted>March 30, 2012</results_first_submitted>
  <results_first_submitted_qc>July 6, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 14, 2012</results_first_posted>
  <last_update_submitted>October 17, 2012</last_update_submitted>
  <last_update_submitted_qc>October 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Steven Rosenberg</investigator_full_name>
    <investigator_title>Dr. Steven Rosenberg</investigator_title>
  </responsible_party>
  <keyword>Disease Free Survival</keyword>
  <keyword>gp 100:209-217 (210m)</keyword>
  <keyword>Immunologic Response</keyword>
  <keyword>Adjuvant Therapy</keyword>
  <keyword>Cutaneous Melanoma</keyword>
  <keyword>Melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Imiquimod</mesh_term>
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>104 subjects were enrolled in this trial.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Adj-3 A2 gp209(2M) in IFA SQ (Vortex)</title>
          <description>gp100:209-217(210M) peptide emulsified in MONTANIDE ISA-51 or Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).</description>
        </group>
        <group group_id="P2">
          <title>Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (Vortex)</title>
          <description>gp100:209-217(210M) peptide emulsified in MONTANIDE ISA-51 or Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of injection daily for 5 days.</description>
        </group>
        <group group_id="P3">
          <title>Adj-3 A2 gp209(2M) in Saline ID</title>
          <description>gp100:209-217(210M) in 0.9% Sodium Chloride Injection injected intradermally on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).</description>
        </group>
        <group group_id="P4">
          <title>Adj-3 A2 gp209(2M) in Saline ID + Imiquimod</title>
          <description>gp100:209-217(210M) peptide in 0.9% Sodium Chloride Injection injected intradermally on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of the injection daily for 5 days.</description>
        </group>
        <group group_id="P5">
          <title>Adj-3 A2 gp209(2M) in IFA SQ (2 Syringe)</title>
          <description>gp100:209-217(210M) peptide emulsified in Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).</description>
        </group>
        <group group_id="P6">
          <title>Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (2 Syringe)</title>
          <description>gp100:209-217(210M) peptide emulsified in Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of injection daily for 5 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="15"/>
                <participants group_id="P6" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="15"/>
                <participants group_id="P6" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adj-3 A2 gp209(2M) in IFA SQ (Vortex)</title>
          <description>gp100:209-217(210M) peptide emulsified in MONTANIDE ISA-51 or Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).</description>
        </group>
        <group group_id="B2">
          <title>Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (Vortex)</title>
          <description>gp100:209-217(210M) peptide emulsified in MONTANIDE ISA-51 or Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of injection daily for 5 days.</description>
        </group>
        <group group_id="B3">
          <title>Adj-3 A2 gp209(2M) in Saline ID</title>
          <description>gp100:209-217(210M) in 0.9% Sodium Chloride Injection injected intradermally on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).</description>
        </group>
        <group group_id="B4">
          <title>Adj-3 A2 gp209(2M) in Saline ID + Imiquimod</title>
          <description>gp100:209-217(210M) peptide in 0.9% Sodium Chloride Injection injected intradermally on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of the injection daily for 5 days.</description>
        </group>
        <group group_id="B5">
          <title>Adj-3 A2 gp209(2M) in IFA SQ (2 Syringe)</title>
          <description>gp100:209-217(210M) peptide emulsified in Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).</description>
        </group>
        <group group_id="B6">
          <title>Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (2 Syringe)</title>
          <description>gp100:209-217(210M) peptide emulsified in Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of injection daily for 5 days.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="18"/>
            <count group_id="B4" value="19"/>
            <count group_id="B5" value="15"/>
            <count group_id="B6" value="14"/>
            <count group_id="B7" value="104"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.9" spread="9.1"/>
                    <measurement group_id="B2" value="42.8" spread="10.4"/>
                    <measurement group_id="B3" value="48.8" spread="12.7"/>
                    <measurement group_id="B4" value="48.1" spread="10.2"/>
                    <measurement group_id="B5" value="51.7" spread="13.2"/>
                    <measurement group_id="B6" value="47.7" spread="8.3"/>
                    <measurement group_id="B7" value="47.6" spread="10.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaskan Natives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian or Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black of non-Hispanic Origin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White of non-Hispanic Origin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other or Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Immunologic Response Rate</title>
        <description>Comparison of six different preparations of the gp100:209-217 (210M) melanoma antigen peptide. The arm with the greater number of immunologic responses will be the one most likely to be selected for future study on the basis of immunization alone. Evidence of immunization consist of at least 10 Elispots/100,000 cells above background. An injection site reaction is not an immune response.</description>
        <time_frame>48 months</time_frame>
        <population>The number of participants analyzed and results are correct. We do not have the immunologic response rate data for all patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Adj-3 A2 gp209(2M) in IFA SQ (Vortex)</title>
            <description>gp100:209-217(210M) peptide emulsified in MONTANIDE ISA-51 or Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (Vortex)</title>
            <description>gp100:209-217(210M) peptide emulsified in MONTANIDE ISA-51 or Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of injection daily for 5 days.</description>
          </group>
          <group group_id="O3">
            <title>Adj-3 A2 gp209(2M) in Saline ID</title>
            <description>gp100:209-217(210M) in 0.9% Sodium Chloride Injection injected intradermally on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).</description>
          </group>
          <group group_id="O4">
            <title>Adj-3 A2 gp209(2M) in Saline ID + Imiquimod</title>
            <description>gp100:209-217(210M) peptide in 0.9% Sodium Chloride Injection injected intradermally on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of the injection daily for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>Adj-3 A2 gp209(2M) in IFA SQ (2 Syringe)</title>
            <description>gp100:209-217(210M) peptide emulsified in Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).</description>
          </group>
          <group group_id="O6">
            <title>Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (2 Syringe)</title>
            <description>gp100:209-217(210M) peptide emulsified in Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of injection daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunologic Response Rate</title>
          <description>Comparison of six different preparations of the gp100:209-217 (210M) melanoma antigen peptide. The arm with the greater number of immunologic responses will be the one most likely to be selected for future study on the basis of immunization alone. Evidence of immunization consist of at least 10 Elispots/100,000 cells above background. An injection site reaction is not an immune response.</description>
          <population>The number of participants analyzed and results are correct. We do not have the immunologic response rate data for all patients.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Here are the number of participants with adverse events. For a detailed list of adverse events see the adverse event module.</description>
        <time_frame>48 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adj-3 A2 gp209(2M) in IFA SQ (Vortex)</title>
            <description>gp100:209-217(210M) peptide emulsified in MONTANIDE ISA-51 or Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (Vortex)</title>
            <description>gp100:209-217(210M) peptide emulsified in MONTANIDE ISA-51 or Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of injection daily for 5 days.</description>
          </group>
          <group group_id="O3">
            <title>Adj-3 A2 gp209(2M) in Saline ID</title>
            <description>gp100:209-217(210M) in 0.9% Sodium Chloride Injection injected intradermally on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).</description>
          </group>
          <group group_id="O4">
            <title>Adj-3 A2 gp209(2M) in Saline ID + Imiquimod</title>
            <description>gp100:209-217(210M) peptide in 0.9% Sodium Chloride Injection injected intradermally on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of the injection daily for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>Adj-3 A2 gp209(2M) in IFA SQ (2 Syringe)</title>
            <description>gp100:209-217(210M) peptide emulsified in Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).</description>
          </group>
          <group group_id="O6">
            <title>Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (2 Syringe)</title>
            <description>gp100:209-217(210M) peptide emulsified in Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of injection daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Here are the number of participants with adverse events. For a detailed list of adverse events see the adverse event module.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Adj-3 A2 gp209(2M) in IFA SQ (Vortex)</title>
          <description>gp100:209-217(210M) peptide emulsified in MONTANIDE ISA-51 or Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).</description>
        </group>
        <group group_id="E2">
          <title>Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (Vortex)</title>
          <description>gp100:209-217(210M) peptide emulsified in MONTANIDE ISA-51 or Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of injection daily for 5 days.</description>
        </group>
        <group group_id="E3">
          <title>Adj-3 A2 gp209(2M) in Saline ID</title>
          <description>gp100:209-217(210M) in 0.9% Sodium Chloride Injection injected intradermally on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).</description>
        </group>
        <group group_id="E4">
          <title>Adj-3 A2 gp209(2M) in Saline ID + Imiquimod</title>
          <description>gp100:209-217(210M) peptide in 0.9% Sodium Chloride Injection injected intradermally on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of the injection daily for 5 days.</description>
        </group>
        <group group_id="E5">
          <title>Adj-3 A2 gp209(2M) in IFA SQ (2 Syringe)</title>
          <description>gp100:209-217(210M) peptide emulsified in Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).</description>
        </group>
        <group group_id="E6">
          <title>Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (2 Syringe)</title>
          <description>gp100:209-217(210M) peptide emulsified in Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of injection daily for 5 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocyte count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Serum phosphate decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="56" subjects_affected="19" subjects_at_risk="19"/>
                <counts group_id="E2" events="48" subjects_affected="19" subjects_at_risk="19"/>
                <counts group_id="E3" events="47" subjects_affected="18" subjects_at_risk="18"/>
                <counts group_id="E4" events="55" subjects_affected="19" subjects_at_risk="19"/>
                <counts group_id="E5" events="35" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E6" events="36" subjects_affected="14" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rash desquamating</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steven A. Rosenberg, M.D.</name_or_title>
      <organization>National Cancer Institute, National Institutes of Health</organization>
      <phone>301-496-4164</phone>
      <email>sar@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

